KZR Stock Summary and Trading Ideas (Kezar Life Sciences | NASDAQ:KZR)

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences trades on the NASDAQ stock market under the symbol KZR.

As of April 28, 2026, KZR stock price climbed to $7.31 with 13,445 million shares trading.

KZR has a beta of 0.80, meaning it tends to be less sensitive to market movements. KZR has a correlation of 0.04 to the broad based SPY ETF.

KZR has a market cap of $53.89 million. This is considered a Micro Cap stock.

Last quarter Kezar Life Sciences reported $0 in Revenue and -$1.99 earnings per share. This fell short of revenue expectation by $-333,330 and missed earnings estimates by -$1.01.

In the last 3 years, KZR traded as high as $31.30 and as low as $3.53.

The top ETF exchange traded funds that KZR belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.

KZR has outperformed the market in the last year with a return of +55.5%, while the SPY ETF gained +30.6%. In the last 3 month period, KZR beat the market returning +17.3%, while SPY returned +2.6%. However, in the most recent 2 weeks KZR has underperformed the stock market by returning -1.6%, while SPY returned +3.7%.

KZR support price is $7.13 and resistance is $7.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZR shares will trade within this expected range on the day.